Collectively, these findings underscore the critical role of ZMYND11 downregulation in promoting prostate cancer cell growth and metastasis both in vitro and in vivo, consistent with the observed association between low ZMYND11 levels, aggressive prostate tumor phenotype, prostate cancer progression, and poor prognosis in clinical settings. The gene discussed is ZMYND11; the disease is prostate carcinoma.